Ginkgo Bioworks Holdings (DNA) Cash & Current Investments (2019 - 2026)

Ginkgo Bioworks Holdings' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $143.9 million for Q1 2026.

• Quarterly Cash & Current Investments fell 53.95% year-over-year to $143.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.9 million (down 53.95% YoY) and the FY2025 annual result came in at $422.6 million, down 24.74% from the prior year.
• Cash & Current Investments was $143.9 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $422.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.5 billion in Q1 2022 and bottomed at $111.1 million in Q3 2025.
• A 5-year average of $809.1 million and a median of $840.4 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 486.14% — and 2025, when it plunged 81.98%.
• Ginkgo Bioworks Holdings' Cash & Current Investments stood at $1.3 billion in 2022, then dropped by 28.36% to $944.1 million in 2023, then sank by 40.52% to $561.6 million in 2024, then declined by 24.74% to $422.6 million in 2025, then plunged by 65.96% to $143.9 million in 2026.
• Business Quant data shows DNA's Cash & Current Investments at $143.9 million in Q1 2026, $422.6 million in Q4 2025, and $111.1 million in Q3 2025.